The Koschmann lab is studying the molecular mechanisms by which mutations in pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) can be therapeutically targeted. The Koschmann Lab’s work in precision medicine pushes the boundaries of targeted therapies and precision diagnostics for children diagnosed with these brain tumors. Through highly collaborative basic, translational, and clinical research, the Koschmann Lab strives towards improving outcomes and providing hope for children fighting these devastating diseases.
Research
Genetic Drivers of Pediatric DMG and DIPG
The Koschmann lab is studying the molecular mechanisms by which mutations promote tumor formation and genetic instability in pediatric diffuse midline glioma (DMG), and diffuse intrinsic pontine glioma (DIPG). Their work is currently focused on how mutations in pediatric and young adult HGG might affect tumor growth, evolution, and response to novel DNA-damaging therapies.
Targeted Therapies for DMG and DIPG
The Koschmann lab is working to develop and understand new molecularly targeted therapies for children and young adults with DMG and DIPG, based on selection of drugs with the highest likelihood of crossing the highly selective blood brain barrier. Their work is focused on optimization of use and combination of the imipridone ONC201 in this patient population.
COrrelate CSF and PLASMA tDNA TRACKING
The Koschmann lab is applying a novel precision medicine approach accounting for both unique tumor biology and optimization of blood brain barrier penetration. We are performing correlate biology work on ongoing precision medicine trials for children and young adults with brain tumors at the University of Michigan, including correlation of spinal fluid analysis with surveillance MRIs.